insights_auto
Outlook: 56.2% bullish·6.2% bearish
Go to analysischevron_right
CURA:TSE
Curaleaf Holdings Inc
CA$13.23
arrow_upward
+0.08%(+0.0100) 1D
Nov 6, 4:00:00 PM GMT-5 · CAD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CURA...
Open
CA$13.28
High
CA$13.71
Low
CA$13.18
Mkt. cap
3.10B
Avg. vol.
317.07K
Volume
337.97K
52-wk high
CA$20.92
52-wk low
CA$7.77
EPS
-CA$0.06
Shares outstanding
233.67M
No. of employees
6K
Open
CA$13.28
High
CA$13.71
Low
CA$13.18
Mkt. cap
3.10B
Avg. vol.
317.07K
Volume
337.97K
52-wk high
CA$20.92
52-wk low
CA$7.77
EPS
-CA$0.06
Shares outstanding
233.67M
No. of employees
6K
News stories
From web sources and news partners
BigGo Finance
·
51 minutes ago
Nasdaq Slides Into Correction as Fear Gauge Hits 'Extreme Fear'; Buffett's Crisis Playbook Back in Focus
24/7 Wall St.
·
33 minutes ago
Bitcoin's Correlation With the S&P 500 Just Hit 0.80. Is Bitcoin Trading Like a Tech Stock Again?
TheStreet
·
5 minutes ago
Why S&P 500 investors may want to look beyond mega-cap tech
Yahoo Finance
·
5 hours ago
Coca-Cola (KO) Makes the Dow’s Low-Upside List While Selling More Drinks, Not Just Charging More
About Curaleaf Holdings Inc
CEO-
Employees5.55K
Founded2014
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitecuraleaf.com
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.11 / -$0.15
+28.67%beat
arrow_upward
Revenue / Est. (USD)
352.65M / 346.39M
+1.81%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 323.36M | 324.23M | 340.10M | 352.65M |
Cost of goods sold | 159.81M | 166.94M | 170.18M | 182.17M |
Cost of revenue | 159.81M | 166.94M | 170.18M | 182.17M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 105.76M | 113.21M | 131.68M | 131.03M |
Operating expense | 153.25M | 156.54M | 165.69M | 167.53M |
Total operating expenses | 313.06M | 323.48M | 335.88M | 349.71M |
Operating income | 10.31M | 753.00K | 4.22M | 2.94M |
Other non operating income | 2.84M | 1.23M | 1.51M | 1.78M |
EBT including unusual items | -16.74M | -28.63M | -26.31M | -22.86M |
EBT excluding unusual items | -11.25M | -24.88M | -24.51M | -22.88M |
Income tax expense | 25.22M | -98.70M | -38.78M | 14.51M |
Effective tax rate | -150.58% | 344.77% | 147.42% | -63.48% |
Other operating expenses | - | - | - | - |
Net income | -59.82M | 69.80M | 12.51M | -32.72M |
Net profit margin | -18.50% | 21.53% | 3.68% | -9.28% |
Earnings per share | -0.15 | 0.29 | 0.07 | -0.11 |
Interest and investment income | 174.00K | 212.00K | 149.00K | 121.00K |
Interest expense | -24.50M | -25.53M | -27.72M | -28.39M |
Net interest expenses | -24.32M | -25.32M | -27.57M | -28.27M |
Depreciation and amortization charges | 35.14M | 33.67M | 34.02M | 36.51M |
EBITDA | 58.37M | 48.61M | 52.83M | 54.48M |
Gain or loss from assets sale | 499.00K | -194.00K | 194.00K | - |
Upcoming events